Literature DB >> 8915239

Pulmonary capillaritis and alveolar hemorrhage. Update on diagnosis and management.

R J Green1, S J Ruoss, S A Kraft, S R Duncan, G J Berry, T A Raffin.   

Abstract

Pulmonary vascular inflammatory disorders may involve all components of the pulmonary vasculature, including capillaries. The principal histopathologic features of pulmonary capillaritis include capillary wall necrosis with infiltration by neutrophils, interstitial erythrocytes, and/or hemosiderin, and interalveolar septal capillary occlusion by fibrin thrombi. Immune complex deposition is variably present. Patients often present clinically with diffuse alveolar hemorrhage, which is characterized by dyspnea and hemoptysis; diffuse, bilateral, alveolar infiltrates on chest radiograph; and anemia. Pulmonary capillaritis has been reported with variable frequency and severity as a manifestation of Wegener's granulomatosis, microscopic polyarteritis, systemic lupus erythematosus, Goodpasture's syndrome, idiopathic pulmonary renal syndrome, Behçet's syndrome, Henoch-Schönlein purpura, IgA nephropathy, antiphospholipid syndrome, progressive systemic sclerosis, and diphenylhydantoin use. In addition to history, physical examination, and routine laboratory studies, certain ancillary laboratory tests, such as antineutrophil cytoplasmic antibodies, antinuclear antibodies, and antiglomerular basement membrane antibodies, may help diagnose an underlying disease. Diagnosis of pulmonary capillaritis can be made by fiberoptic bronchoscopy with transbronchial biopsy, but thoracoscopic biopsy is often employed. Since many disorders can result in pulmonary capillaritis with diffuse alveolar hemorrhage, it is crucial for clinicians and pathologists to work together when attempting to identify an underlying disease. Therapy depends on the disorder that gave rise to the pulmonary capillaritis and usually includes corticosteroids and cyclophosphamide or azathioprine. Since most diseases that result in pulmonary capillaritis are treated with immunosuppression, infection must be excluded aggressively.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8915239     DOI: 10.1378/chest.110.5.1305

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  37 in total

Review 1.  Small vessel vasculitis of the lung.

Authors:  M I Schwarz; K K Brown
Journal:  Thorax       Date:  2000-06       Impact factor: 9.139

2.  Gemcitabine-associated diffuse alveolar hemorrhage.

Authors:  P L Carron; L Cousin; T Caps; E Belle; D Pernet; A Neidhardt; G Capellier
Journal:  Intensive Care Med       Date:  2001-09       Impact factor: 17.440

Review 3.  Imaging of the pulmonary manifestations of systemic disease.

Authors:  A G Rockall; D Rickards; P J Shaw
Journal:  Postgrad Med J       Date:  2001-10       Impact factor: 2.401

Review 4.  The lung in systemic vasculitis: radiological patterns and differential diagnosis.

Authors:  Beatrice Feragalli; Cesare Mantini; Marco Sperandeo; Michele Galluzzo; Giovanni Belcaro; Armando Tartaro; Antonio R Cotroneo
Journal:  Br J Radiol       Date:  2016-02-15       Impact factor: 3.039

5.  Radiological aspects of diffuse alveolar haemorrhage.

Authors:  G Cortese; R Nicali; R Placido; G Gariazzo; P Anrò
Journal:  Radiol Med       Date:  2008-02-25       Impact factor: 3.469

Review 6.  Diffuse Alveolar Hemorrhage in Cardiac Diseases.

Authors:  Biplab K Saha; Woon H Chong
Journal:  Lung       Date:  2021-03-11       Impact factor: 2.584

7.  Metastatic angiosarcoma presenting as diffuse alveolar hemorrhage.

Authors:  Sp Rai; Ms Barthwal; P Bhattacharya; S Bhargava; M Pethe
Journal:  Lung India       Date:  2008-01

8.  Diffuse alveolar haemorrhage secondary to warfarin therapy for atrial fibrillation: a case report and literature review.

Authors:  Abdelkarim Waness; Tarek Aldabbagh; Mohammed Harakati
Journal:  BMJ Case Rep       Date:  2009-03-17

9.  Prognostic factors for hospital mortality and ICU admission in patients with ANCA-related pulmonary vasculitis.

Authors:  Fernando Holguin; Bassel Ramadan; Anthony A Gal; Jesse Roman
Journal:  Am J Med Sci       Date:  2008-10       Impact factor: 2.378

10.  Chronic catastrophic-like antiphospholipid syndrome: a “smoldering” variant?

Authors:  Daniel Athanazio; Maria Cristina Rocha; Túlio Geraldo de Souza e Souza; Natália Oliveira e Silva; Sérgio Jezler; Mittermayer Barreto Santiago
Journal:  Rheumatol Int       Date:  2009-11       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.